SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

被引：6
|
作者：
Sulkowski, M. [1 ]
Bourliere, M. [2 ]
Bronowicki, J. -P. [3 ]
Streinu-Cercel, A. [4 ]
Preotescu, L. [4 ]
Asselah, T. [5 ]
Pawlotsky, J. -M. [6 ]
Shafran, S. [7 ]
Pol, S. [8 ]
Caruntu, F. A. [4 ]
Mauss, S. [9 ]
Larrey, D. [10 ]
Haefner, C. [11 ]
Datsenko, Y. [11 ]
Stern, J. [12 ]
Kubiak, R. [11 ]
Steinmann, G. [11 ]
机构：
[1] Johns Hopkins Univ, Dept Viral Hepatitis, Baltimore, MD USA
[2] Hop St Joseph, Marseille, France
[3] Hop Brabois, Vandoeuvre Les Nancy, France
[4] Prof Dr Matei Bals Inst Infect Dis 1, Bucharest, Romania
[5] Hop Beaujon, Clichy, France
[6] Hop Henri Mondor, F-94010 Creteil, France
[7] Univ Alberta, Edmonton, AB, Canada
[8] Hop Cochin, F-75674 Paris, France
[9] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany
[10] Hop St Eloi, Montpellier, France
[11] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[12] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
来源：
JOURNAL OF HEPATOLOGY | 2010年 / 52卷
关键词：
D O I：
10.1016/S0168-8278(10)61191-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S462 / S463
页数：2
相关论文
共 50 条
  • [31] ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS
    Lalezari, J.
    Poordad, F.
    Mehra, P.
    Nguyen, T.
    Dejesus, E.
    Godofsky, E.
    Patrick, G. Dubuc
    Chen, J.
    Pietropaolo, K.
    Zhou, X. -J.
    Sullivan-Bolyai, J. Z.
    Mayers, D.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S469 - S469
  • [32] The role of cholesterol on sustained virological response (SVR) in the treatment of genotype-1 infected hepatitis C (CHC) patients with peginterferon-alfa-2a (PEG) and ribavirin (RBV)
    Mauss, S.
    Zehnter, E.
    Hueppe, D.
    Kaiser, K.
    Boeker, K.
    Lutz, T.
    Heyne, R.
    John, C.
    Moog, G.
    Schober, A.
    Pfaff, R.
    Zipf, A.
    Racky, S.
    Lohmeyer, J.
    Bokemeyer, B.
    Kallinowski, B.
    Witthoeft, T.
    Alshuth, U.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S304 - S304
  • [33] HCV-RNA status at week 12 of treatment with peginterferon alfa-2a/RBV predicts SVR in patients with prior non-response to pegylated interferon alfa-2b/RBV: Results from repeat study
    Marcellin, P.
    Freilich, B.
    Andreone, P.
    DiBisceglie, A.
    Brandao, C. E.
    Reddy, K. R.
    Craxi, A.
    Olveira, A.
    Teuber, G.
    Messinger, D.
    Hooper, G.
    Popescu, M.
    Tietz, A.
    Jensen, D.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S301 - S301
  • [34] HCV-RNA status at week 12 of treatment with peginterferon Alfa-2a/RBV predicts SVR in patients with prior non-response to pegylated interferon Alfa-2b/RBV: Results from repeat study
    Marcellin, Patrick
    Freilich, Bradley L.
    Andreone, Pietro
    Di Bisceglie, Adrian M.
    Brandao-Mello, Carlos E.
    Reddy, K. Rajender
    Craxi, Antonio
    Olveira, Antonio
    Teuber, Gerlinde
    Messinger, Diethelm
    Hooper, Greg
    Popescu, Matei
    Jensen, Donald M.
    GASTROENTEROLOGY, 2008, 134 (04) : A788 - A788
  • [35] Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1
    Jeffers, LJ
    Cassidy, W
    Howell, CD
    Hu, S
    Reddy, KR
    HEPATOLOGY, 2004, 39 (06) : 1702 - 1708
  • [36] Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
    Pijak, MR
    Gazdik, F
    Hrusovsky, S
    HEPATOLOGY, 2004, 40 (03) : 760 - 761
  • [37] Peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC)
    Fargion, S
    Borzio, M
    Cargnel, A
    JOURNAL OF HEPATOLOGY, 2003, 38 : 139 - 140
  • [38] RETREATMENT WITH PEGINTERFERON (PEG-IFN) ALFA-2B PLUS RIBAVIRIN (RBV) OF CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS WHO WERE NONRESPONDERS TO PEGINTERFERON ALFA-2A: FINAL RESULTS OF ESPECIAL
    Zeuzem, Stefan
    Diago, Moises
    Pohle, Thorsten
    Andriulli, Angelo
    Spengler, Ulrich
    Gatta, Angelo
    Maieron, Andreas
    Herold, Christoph
    Yu, Xin
    Faruqi, Rab
    Chaudhri, Eirum I.
    Pedicone, Lisa
    HEPATOLOGY, 2009, 50 (04) : 684A - 685A
  • [39] Effect of high-dose ribavirin (RBV), Alinia (Nitazoxanide) and pegylated interferon (PegIFN) alfa-2a in attaining sustained virologic response (SVR) in treatment of chronic hepatitis C (ERAIS-C Trial) in naive genotype 1 patients
    Basu, P. P.
    Rayapudi, K.
    Pacana, T.
    Shah, N. J.
    Krishnaswamy, N.
    Hampole, H.
    Tang, C.
    Brown, R.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : S1 - S2
  • [40] Peginterferon alfa-2a/ribavirin treatment in patients with chronic HCV genotype 1: Efficacy is improved in patients with early stages of fibrosis
    Shiffman, ML
    Fried, MW
    Marcellin, P
    Govindarajan, S
    Lopez-Talavera, JC
    Pockros, PJ
    GASTROENTEROLOGY, 2005, 128 (04) : A722 - A722
12345